

John Buse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7048183/publications.pdf>

Version: 2024-02-01

534
papers

112,096
citations

477

133
h-index

170

327
g-index

555
all docs

555
docs citations

555
times ranked

61605
citing authors

#	ARTICLE	IF	CITATIONS
1	Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. <i>Diabetes Care</i> , 2022, 45, 204-212.	4.3	25
2	Islet Autoimmunity Is Highly Prevalent and Associated With Diminished β -Cell Function in Patients With Type 2 Diabetes in the GRADE Study. <i>Diabetes</i> , 2022, 71, 1261-1271.	0.3	11
3	Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure. <i>Journal of the American Heart Association</i> , 2022, 11, e022376.	1.6	14
4	Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. <i>Circulation</i> , 2022, 145, 575-585.	1.6	88
5	Glycemic Control and Clinical Outcomes in U.S. Patients With COVID-19: Data From the National COVID Cohort Collaborative (N3C) Database. <i>Diabetes Care</i> , 2022, 45, 1099-1106.	4.3	15
6	Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac066.	0.4	17
7	Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS). <i>Drugs - Real World Outcomes</i> , 2022, , 1.	0.7	16
8	A new class of drug in the diabetes toolbox. <i>Nature Medicine</i> , 2022, 28, 901-902.	15.2	3
9	Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1439-1447.	2.2	2
10	Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg vs. 1.0 mg by Baseline HbA1c and BMI: SUSTAIN FORTE Subgroup Analyses. <i>Diabetologie Und Stoffwechsel</i> , 2022, , .	0.0	0
11	Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 46-52.	5.5	103
12	Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 70-77.	2.4	6
13	The demise of islet allotransplantation in the United States: A call for an urgent regulatory update. <i>American Journal of Transplantation</i> , 2021, 21, 1365-1375.	2.6	33
14	Developing Insulin Delivery Devices with Glucose Responsiveness. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 31-44.	4.0	25
15	Managing the risks and benefits of clinical research in response to a pandemic. <i>Journal of Clinical and Translational Science</i> , 2021, 5, .	0.3	4
16	Re-engineering The Clinical Research Enterprise in Response to COVID-19: The Clinical Translational Science Award (CTSA) experience and proposed playbook for future pandemics. <i>Journal of Clinical and Translational Science</i> , 2021, 5, e96.	0.3	11
17	Metabolic state and gustatory perception shapes dynamic interplay between cortical excitability and motor response. <i>Brain Stimulation</i> , 2021, 14, 202-205.	0.7	2
18	The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 960-968.	4.3	21

#	ARTICLE	IF	CITATIONS
19	Experimental increase of blood glucose alters resting state EEG measures of excitationâ€“inhibition balance. <i>Experimental Physiology</i> , 2021, 106, 803-811.	0.9	1
20	Injectable Biodegradable Polymeric Complex for Glucose-Responsive Insulin Delivery. <i>ACS Nano</i> , 2021, 15, 4294-4304.	7.3	29
21	Outpatient metformin use is associated with reduced severity of COVIDâ€“19 disease in adults with overweight or obesity. <i>Journal of Medical Virology</i> , 2021, 93, 4273-4279.	2.5	41
22	Carbohydrate Intake Prior to Oral Glucose Tolerance Testing. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab049.	0.1	16
23	Applying <scp>REWIND</scp> cardiovascular disease criteria to <scp>SUSTAIN</scp> 6 and <scp>PIONEER</scp> 6: An exploratory analysis of cardiovascular outcomes with semaglutide. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1677-1680.	2.2	4
24	Positioning newer drugs in the management of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 139-140.	5.5	3
25	Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. <i>Diabetic Medicine</i> , 2021, 38, e14552.	1.2	5
26	Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses. <i>Diabetes Therapy</i> , 2021, 12, 1099-1116.	1.2	8
27	A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment. <i>Diabetes Care</i> , 2021, 44, 1410-1418.	4.3	10
28	A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. <i>Diabetes Care</i> , 2021, 44, 1595-1603.	4.3	41
29	Back Cover Image, Volume 93, Number 7, July 2021. <i>Journal of Medical Virology</i> , 2021, 93, ii.	2.5	0
30	Prototype of an evidenceâ€“based tool to aid individualized treatment for type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1666-1671.	2.2	4
31	Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1983-1988.	2.2	3
32	Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2262.	3.8	182
33	Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodiumâ€“Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes. <i>Diabetes Care</i> , 2021, 44, 1564-1572.	4.3	43
34	Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2058-2066.	2.2	33
35	Arguments against the Requirement of a Biological License Application for Human Pancreatic Islets: The Position Statement of the Islets for US Collaborative Presented during the FDA Advisory Committee Meeting. <i>Journal of Clinical Medicine</i> , 2021, 10, 2878.	1.0	3
36	Association of Glycemia, Lipids, and Blood Pressure With Cognitive Performance in People With Type 2 Diabetes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes Care</i> , 2021, 44, 2286-2292.	4.3	4

#	ARTICLE	IF	CITATIONS
37	Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative. JAMA Network Open, 2021, 4, e2116901.	2.8	179
38	Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies. Clinical Pharmacology and Therapeutics, 2021, 110, 723-732.	2.3	6
39	100 years on: the impact of the discovery of insulin on clinical outcomes. BMJ Open Diabetes Research and Care, 2021, 9, e002373.	1.2	7
40	Further RISE™ing to the Challenge of Type 2 Diabetes in Youth. Diabetes Care, 2021, 44, 1934-1937.	4.3	1
41	Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes and Endocrinology, 2021, 9, 563-574.	5.5	79
42	The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Diabetes Care, 2021, 44, 2729-2737.	4.3	24
43	Causal role of frontal-midline theta in cognitive effort: a pilot study. Journal of Neurophysiology, 2021, 126, 1221-1233.	0.9	12
44	Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes. Diabetes Care, 2021, 44, e32-e34.	4.3	12
45	COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care, 2021, 44, 2645-2655.	4.3	164
46	Comparison of Protocols to Reduce Diabetic Ketoacidosis in Patients With Type 1 Diabetes Prescribed a Sodium-Glucose Cotransporter 2 Inhibitor. Diabetes Spectrum, 2021, 34, 42-51.	0.4	4
47	Deintensification of Treatment With Sulfonylurea and Insulin After Severe Hypoglycemia Among Older Adults With Diabetes. JAMA Network Open, 2021, 4, e2132215.	2.8	9
48	Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE. BMJ Open Diabetes Research and Care, 2021, 9, e002339.	1.2	12
49	Islets Transplantation at a Crossroads - Need for Urgent Regulatory Update in the United States: Perspective Presented During the Scientific Sessions 2021 at the American Diabetes Association Congress. Frontiers in Endocrinology, 2021, 12, 789526.	1.5	4
50	Glucose-Responsive Insulin and Delivery Systems: Innovation and Translation. Advanced Materials, 2020, 32, e1902004.	11.1	138
51	Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes. Diabetes Care, 2020, 43, 398-404.	4.3	23
52	Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11). Diabetes Therapy, 2020, 11, 53-70.	1.2	18
53	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care, 2020, 43, 643-652.	4.3	38
54	2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2020, 63, 221-228.	2.9	368

#	ARTICLE	IF	CITATIONS
55	2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2020, 43, 487-493.	4.3	846
56	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. <i>Diabetes Care</i> , 2020, 43, 446-452.	4.3	63
57	Evidence for gene-smoking interactions for hearing loss and deafness in Japanese American families. <i>Hearing Research</i> , 2020, 387, 107875.	0.9	5
58	Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2248-2256.	2.2	8
59	The trials and tribulations of determining HbA1c targets for diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2020, 16, 717-730.	4.3	39
60	Real-world evidence: the devil is in the detail. <i>Diabetologia</i> , 2020, 63, 1694-1705.	2.9	38
61	Dual self-regulated delivery of insulin and glucagon by a hybrid patch. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 29512-29517.	3.3	64
62	Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2487-2492.	2.2	31
63	Comprehensive Pulmonary Safety Review of Inhaled Technosphere [®] Insulin in Patients with Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2020, 40, 973-983.	1.1	7
64	Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier's gangrene. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000985.	1.2	19
65	Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107706.	1.2	3
66	Draft FDA guidance for assessing the safety of glucose lowering therapies: a missed opportunity?. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 810-811.	5.5	4
67	Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00637.	1.1	8
68	Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure. <i>Diabetes Care</i> , 2020, 43, 2121-2127.	4.3	7
69	Bibliometrics approach to evaluating the research impact of CTSA: A pilot study. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 336-344.	0.3	13
70	Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12). <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412097093.	0.9	6
71	4300 Evaluation and structure of the pilot funding program at the University of North Carolina CTSA Hub (NC TraCS). <i>Journal of Clinical and Translational Science</i> , 2020, 4, 72-72.	0.3	0
72	4299 The University of North Carolina CTSA Hub (NC TraCS) Service Evaluation: Using Customer Feedback to Improve Services. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 75-75.	0.3	0

#	ARTICLE	IF	CITATIONS
73	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2020, 43, 1546-1552.	4.3	92
74	The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1690-1695.	2.2	19
75	Inpatient Transition to Virtual Care During COVID-19 Pandemic. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 444-448.	2.4	85
76	COVID-19 in People With Diabetes: Urgently Needed Lessons From Early Reports. <i>Diabetes Care</i> , 2020, 43, 1378-1381.	4.3	71
77	Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. <i>Diabetes Care</i> , 2020, 43, 1695-1703.	4.3	147
78	Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. <i>Diabetes Care</i> 2019;42:1912-1920. <i>Diabetes Care</i> , 2020, 43, e30-e31.	4.3	1
79	Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic Cancer. <i>Oncologist</i> , 2020, 25, 579-584.	1.9	25
80	<i>PPARA</i> Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. <i>Diabetes</i> , 2020, 69, 771-783.	0.3	28
81	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1128-1141.	1.2	53
82	Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. <i>Circulation</i> , 2020, 141, 1360-1370.	1.6	9
83	Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results. <i>American Journal of Nephrology</i> , 2020, 51, 276-288.	1.4	9
84	Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. <i>Diabetes Care</i> , 2020, 43, 940-947.	4.3	14
85	A Special Thanks to the Reviewers of <i>Diabetes Care</i> . <i>Diabetes Care</i> , 2020, 43, 939-939.	4.3	0
86	Characterizing the weight-glycemia phenotypes of type 1 diabetes in youth and young adulthood. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000886.	1.2	5
87	Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. <i>Diabetes Care</i> , 2020, 43, e108-e110.	4.3	34
88	Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2193-2198.	2.2	11
89	Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2026-2034.	2.9	18
90	Glucose-Responsive Systems: Glucose-Responsive Insulin and Delivery Systems: Innovation and Translation (<i>Adv. Mater.</i> 13/2020). <i>Advanced Materials</i> , 2020, 32, 2070102.	11.1	3

#	ARTICLE	IF	CITATIONS
91	Risk of severe hypoglycaemia and its impact in type 2 diabetes in <scp>DEVOTE</scp>. Diabetes, Obesity and Metabolism, 2020, 22, 2241-2247.	2.2	11
92	Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the <scp>DEVOTE</scp>, <scp>LEADER</scp> and <scp>SUSTAIN</scp> cardiovascular outcomes trials. Diabetes, Obesity and Metabolism, 2020, 22, 1537-1547.	2.2	54
93	Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry. Thyroid, 2020, 30, 1397-1398.	2.4	5
94	Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs. Nature Biomedical Engineering, 2020, 4, 499-506.	11.6	353
95	Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial. BMJ Open Diabetes Research and Care, 2020, 8, e001649.	1.2	16
96	21-LB: Derived Time-in-Range Is Associated with MACE in T2D: Data from the DEVOTE Trial. Diabetes, 2020, 69, .	0.3	8
97	957-P: Efficacy of Oral Semaglutide According to Background Medication: An Exploratory Subgroup Analysis of the PIONEER Trial Program. Diabetes, 2020, 69, 957-P.	0.3	1
98	2160-PUB: Development of an Evidence-Based Tool to Facilitate Individualized Treatment in the Clinic for Patients with Type 2 Diabetes. Diabetes, 2020, 69, 2160-PUB.	0.3	0
99	122-LB: The Simplici-T1 Trial: Glucokinase Activator TTP399 Improves Glycemic Control in Patients with Type 1 Diabetes. Diabetes, 2020, 69, .	0.3	0
100	123-LB: The Simplici-T1 Trial: Relationship between Glycemic Control and Insulin Dose. Diabetes, 2020, 69, .	0.3	0
101	Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care, 2019, 42, 1912-1920.	4.3	35
102	SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES â€“ A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	4
103	FP482EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	3
104	FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) â€“ A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	4
105	Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. Diabetes, Obesity and Metabolism, 2019, 21, 2450-2458.	2.2	8
106	Charge-switchable polymeric complex for glucose-responsive insulin delivery in mice and pigs. Science Advances, 2019, 5, eaaw4357.	4.7	104
107	Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). Applied Health Economics and Health Policy, 2019, 17, 615-627.	1.0	10
108	Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. Metabolism: Clinical and Experimental, 2019, 98, 104-111.	1.5	18

#	ARTICLE	IF	CITATIONS
109	Reasons for Increases in Complications of Diabetes. JAMA - Journal of the American Medical Association, 2019, 322, 1518.	3.8	3
110	Insights Into Patients' Experience With Type 1 Diabetes: Exit Interviews From Phase III Studies of Sotagliflozin. Clinical Therapeutics, 2019, 41, 2219-2230.e6.	1.1	7
111	IMPACT OF MICROVASCULAR DISEASE ON CARDIORENAL OUTCOMES IN TYPE 2 DIABETES: AN ANALYSIS FROM THE LEADER AND SUSTAIN 6 CLINICAL TRIALS. Canadian Journal of Cardiology, 2019, 35, S147.	0.8	0
112	Longitudinal Phenotypes of Type 1 Diabetes in Youth Based on Weight and Glycemia and Their Association With Complications. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6003-6016.	1.8	12
113	Occurrence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events. JAMA Cardiology, 2019, 4, 1214.	3.0	39
114	88 - Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Baseline Blood Pressure Categories: LEADER and SUSTAIN 6. Canadian Journal of Diabetes, 2019, 43, S32-S33.	0.4	0
115	Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovascular Diabetology, 2019, 18, 138.	2.7	48
116	Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults. Diabetes Care, 2019, 42, 2065-2074.	4.3	8
117	Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring. Diabetes Technology and Therapeutics, 2019, 21, 682-690.	2.4	4
118	Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care, 2019, 42, 2262-2271.	4.3	146
119	Bringing closure: towards achieving a better understanding of Israel. Lancet, The, 2019, 394, 559.	6.3	1
120	A Mixed-Methods, Randomized Clinical Trial to Examine Feasibility of a Mindfulness-Based Stress Management and Diabetes Risk Reduction Intervention for African Americans with Prediabetes. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-16.	0.5	25
121	Sodium-glucose co-transporter ² inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers. Diabetes, Obesity and Metabolism, 2019, 21, 1223-1236.	2.2	29
122	Performance of a computable phenotype for identification of patients with diabetes within PCORnet: The Patient-Centered Clinical Research Network. Pharmacoepidemiology and Drug Safety, 2019, 28, 632-639.	0.9	18
123	A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes: Results From the ACCORD and BARI 2D Studies. Diabetes, 2019, 68, 1649-1662.	0.3	22
124	Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting. Diabetes Care, 2019, 42, e89-e91.	4.3	6
125	Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example. Diabetes, Obesity and Metabolism, 2019, 21, 2203-2210.	2.2	55
126	Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes and Endocrinology, the, 2019, 7, 528-539.	5.5	156

#	ARTICLE	IF	CITATIONS
127	Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2096-2106.	2.2	6
128	Identification of clinically relevant dysglycemia phenotypes based on continuous glucose monitoring data from youth with type 1 diabetes and elevated hemoglobin A1c. <i>Pediatric Diabetes</i> , 2019, 20, 556-566.	1.2	8
129	Glucose transporter inhibitor-conjugated insulin mitigates hypoglycemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10744-10748.	3.3	38
130	PATIENTS WITH DIABETES AND PERIPHERAL ARTERIAL DISEASE: RESULTS FROM THE EXSCEL TRIAL. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2040.	1.2	1
131	Evidence supports prediabetes treatment. <i>Science</i> , 2019, 364, 341-342.	6.0	18
132	Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes Care</i> , 2019, 42, 1075-1080.	4.3	15
133	Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. <i>Diabetes Care</i> , 2019, 42, 919-930.	4.3	51
134	Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1745-1751.	2.2	22
135	Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1625-1633.	2.2	18
136	Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1437-1444.	2.2	13
137	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. <i>Diabetes Care</i> , 2019, 42, 1147-1154.	4.3	249
138	Pioglitazone Therapy in Patients With Stroke and Prediabetes. <i>JAMA Neurology</i> , 2019, 76, 526.	4.5	83
139	Identifying individual risk rare variants using protein structure guided local tests (POINT). <i>PLoS Computational Biology</i> , 2019, 15, e1006722.	1.5	11
140	Characteristics and Delivery of Diabetes Shared Medical Appointments in North Carolina. <i>North Carolina Medical Journal</i> , 2019, 80, 261-268.	0.1	4
141	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008018.	1.4	25
142	Glucose-responsive oral insulin delivery for postprandial glycemic regulation. <i>Nano Research</i> , 2019, 12, 1539-1545.	5.8	61
143	Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 854-865.	2.2	6
144	Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	47

#	ARTICLE	IF	CITATIONS
145	Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System. <i>Diabetes Care</i> , 2019, 42, e21-e23.	4.3	17
146	Advances in transdermal insulin delivery. <i>Advanced Drug Delivery Reviews</i> , 2019, 139, 51-70.	6.6	202
147	Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. <i>Annals of Internal Medicine</i> , 2019, 170, 423.	2.0	34
148	Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 525-532.	2.2	21
149	6-LB: Effect of Open-Label SGLT2 Inhibitor Treatment When Combined with Exenatide on Cardiovascular and Renal Outcomes in EXSCEL. <i>Diabetes</i> , 2019, 68, 6-LB.	0.3	1
150	985-P: Oral Semaglutide as Add-On to Insulin in T2D: PIONEER 8. <i>Diabetes</i> , 2019, 68, .	0.3	7
151	1643-P: Prevalence of Diabetes Medication Regimens in PCORnet, the National Patient-Centered Clinical Research Network. <i>Diabetes</i> , 2019, 68, .	0.3	0
152	321-OR: A Genetic Locus on Chromosome 1p36 Associated with Cardiovascular Autonomic Neuropathy in Type 2 Diabetes. <i>Diabetes</i> , 2019, 68, .	0.3	0
153	15-LB: Diabetes Duration Did Not Moderate the Reduction in Severe Hypoglycemia Seen with Degludec vs. Glargine U100 in DEVOTE. <i>Diabetes</i> , 2019, 68, .	0.3	0
154	983-P: Effect and Safety of Flexible Dose Adjustment with Oral Semaglutide vs. Sitagliptin in Type 2 Diabetes: PIONEER 7. <i>Diabetes</i> , 2019, 68, 983-P.	0.3	1
155	1141-P: Detailed Phenotype of Randomized Participants by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes</i> , 2019, 68, 1141-P.	0.3	0
156	8-LB: Outcomes of Type 2 Diabetes (T2D) Clustering Replicated in the DEVOTE Trial. <i>Diabetes</i> , 2019, 68, .	0.3	1
157	Bioresponsive Microneedles with a Sheath Structure for H ₂ O ₂ and pH Cascade-Triggered Insulin Delivery. <i>Small</i> , 2018, 14, e1704181.	5.2	113
158	Genetic Variants in <i>CPA6</i> and <i>PRPF31</i> Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1428-1440.	0.3	32
159	The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults. <i>Diabetes Care</i> , 2018, 41, 1196-1203.	4.3	6
160	Core-Shell Microneedle Gel for Self-Regulated Insulin Delivery. <i>ACS Nano</i> , 2018, 12, 2466-2473.	7.3	207
161	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a <i>Diabetes Care</i> Editors' Expert Forum. <i>Diabetes Care</i> , 2018, 41, 14-31.	4.3	338
162	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. <i>Diabetes Care</i> , 2018, 41, 596-603.	4.3	59

#	ARTICLE	IF	CITATIONS
163	Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 105-113.	5.5	451
164	DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK. <i>Diabetes Therapy</i> , 2018, 9, 1217-1232.	1.2	11
165	Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1732-1739.	2.2	5
166	Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). <i>American Journal of Cardiology</i> , 2018, 121, 1467-1470.	0.7	25
167	Genetic Variants in <i>HSD17B3</i> , <i>SMAD3</i> , and <i>IPO11</i> Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 712-721.	2.3	30
168	Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 129-140.	2.2	14
169	Synthetic beta cells for fusion-mediated dynamic insulin secretion. <i>Nature Chemical Biology</i> , 2018, 14, 86-93.	3.9	184
170	DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. <i>Diabetologia</i> , 2018, 61, 58-65.	2.9	124
171	Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). <i>Diabetologia</i> , 2018, 61, 48-57.	2.9	126
172	Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD. <i>Diabetes Care</i> , 2018, 41, 348-355.	4.3	16
173	Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial. <i>Diabetes Care</i> , 2018, 41, 333-340.	4.3	41
174	Health Literacy, Glycemic Control, and Physician-Advised Glucose Self-Monitoring Use in Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2018, 31, 344-347.	0.4	5
175	LIRAGLUTIDE REDUCES CARDIOVASCULAR EVENTS AND MORTALITY IN TYPE 2 DIABETES INDEPENDENT OF LDL CHOLESTEROL AND STATIN USE: RESULTS OF THE LEADER TRIAL. <i>Canadian Journal of Cardiology</i> , 2018, 34, S123-S124.	0.8	0
176	Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. <i>Diabetes Care</i> , 2018, 41, 2404-2413.	4.3	32
177	Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2885-2893.	2.2	44
178	Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e009304.	1.6	19
179	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2018, 61, 2461-2498.	2.9	1,002
180	Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2018, 41, 2669-2701.	4.3	2,190

#	ARTICLE	IF	CITATIONS
181	Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1693-1702.	2.2	32
182	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. <i>Circulation</i> , 2018, 138, 2884-2894.	1.6	82
183	Liraglutide and Glycaemic Outcomes in the LEADER Trial. <i>Diabetes Therapy</i> , 2018, 9, 2383-2392.	1.2	23
184	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease. <i>Circulation</i> , 2018, 137, 2179-2183.	1.6	80
185	Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes?. <i>Diabetes Care</i> , 2018, 41, 1560-1562.	4.3	10
186	Calendar time as an instrumental variable in assessing the risk of heart failure with antihyperglycemic drugs. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 857-866.	0.9	8
187	Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. <i>Diabetes Care</i> , 2018, 41, 1970-1980.	4.3	170
188	Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE4D). <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2585-2597.	2.2	164
189	Management of Type 1 Diabetes With a Very Low-Carbohydrate Diet: A Word of Caution. <i>Pediatrics</i> , 2018, 142, e20181536B.	1.0	13
190	The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. <i>Diabetes Care</i> , 2018, 41, 2229-2235.	4.3	74
191	Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2522-2533.	1.8	7
192	Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults. <i>Diabetes Care</i> , 2018, 41, 1998-2009.	4.3	32
193	Primum Non Nocere: Refocusing Our Attention on Severe Hypoglycemia Prevention. <i>Diabetes Care</i> , 2018, 41, 1557-1559.	4.3	5
194	Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 571-575.	2.4	68
195	Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. <i>Circulation</i> , 2018, 138, 1605-1607.	1.6	25
196	Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. <i>Diabetes Care</i> , 2018, 41, 1663-1671.	4.3	51
197	Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. <i>Diabetes Care</i> , 2018, 41, 1783-1791.	4.3	82
198	Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. <i>Diabetes Care</i> , 2018, 41, 1792-1800.	4.3	25

#	ARTICLE	IF	CITATIONS
199	Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2532-2540.	2.2	133
200	Efficacy and Safety of Faster Aspart Compared with Insulin Aspart Both with Insulin Degludec in Adults with T1D. <i>Diabetes</i> , 2018, 67, 1000-P.	0.3	2
201	Increased Time-in-Range with Sotagliflozin as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes as Demonstrated by 24-Week Continuous Glucose Monitoring (inTandem1, inTandem2). <i>Diabetes</i> , 2018, 67, 1179-P.	0.3	2
202	Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1). <i>Diabetes</i> , 2018, 67, 212-OR.	0.3	4
203	Canagliflozin (CANA) vs. Other Antihyperglycemic Agents on the Risk of Below-Knee Amputation (BKA) for Patients with T2DM—A Real-World Analysis of >700,000 U.S. Patients. <i>Diabetes</i> , 2018, 67, .	0.3	3
204	Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes</i> , 2018, 67, .	0.3	42
205	Latest Developments in Continuous Glucose Monitoring, Insulin, and Adjunctive Treatments in Type 1 Diabetes. <i>US Endocrinology</i> , 2018, 14, 54.	0.3	0
206	Simplici-T1—First Clinical Trial to Test Activation of Glucokinase as an Adjunctive Treatment for Type 1 Diabetes. <i>Diabetes</i> , 2018, 67, 126-LB.	0.3	1
207	A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 56-OR.	0.3	0
208	Implementation and Evaluation of Shared Medical Appointments for Type 2 Diabetes at a Free, Student-Run Clinic in Alamance County, North Carolina. , 2018, 2, .		3
209	Hypoxia and H ₂ O ₂ Dual-Sensitive Vesicles for Enhanced Glucose-Responsive Insulin Delivery. <i>Nano Letters</i> , 2017, 17, 733-739.	4.5	220
210	No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 970-978.	2.2	17
211	Red Blood Cells for Glucose-Responsive Insulin Delivery. <i>Advanced Materials</i> , 2017, 29, 1606617.	11.1	126
212	Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a <i>Diabetes Care</i> Editors' Expert Forum. <i>Diabetes Care</i> 2016;39:1186-1201. <i>Diabetes Care</i> , 2017, 40, e23-e24.	4.3	1
213	Differential Use of Screening Mammography in Older Women Initiating Metformin versus Sulfonylurea. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 666-675.	0.9	2
214	Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women. <i>Epidemiology</i> , 2017, 28, 446-454.	1.2	15
215	Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. <i>Diabetes Care</i> , 2017, 40, 966-972.	4.3	63
216	Drug Delivery Devices: Insulin-Responsive Glucagon Delivery for Prevention of Hypoglycemia (Small) Tj ETQq0 0 0,rgBT /Overlock 10 Tf	5.2	0

#	ARTICLE	IF	CITATIONS
217	Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings. <i>JAMA Internal Medicine</i> , 2017, 177, 920.	2.6	114
218	Prevalence of Celiac Disease in 52,721 Youth With Type 1 Diabetes: International Comparison Across Three Continents. <i>Diabetes Care</i> , 2017, 40, 1034-1040.	4.3	104
219	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 644-657.	13.9	5,629
220	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 723-732.	13.9	480
221	Sodium-Glucose Cotransporter 2 Inhibitors and Diabetic Ketoacidosis: A Case Series From Three Academic Institutions. <i>Diabetes Care</i> , 2017, 40, e65-e66.	4.3	19
222	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>American Heart Journal</i> , 2017, 187, 1-9.	1.2	49
223	Insulin-Responsive Glucagon Delivery for Prevention of Hypoglycemia. <i>Small</i> , 2017, 13, 1603028.	5.2	36
224	Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , 2017, 2, 370.	3.0	136
225	H ₂ O ₂ -Responsive Vesicles Integrated with Transcutaneous Patches for Glucose-Mediated Insulin Delivery. <i>ACS Nano</i> , 2017, 11, 613-620.	7.3	255
226	Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. <i>Lancet, The</i> , 2017, 389, 369-380.	6.3	207
227	5. Prevention or Delay of Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, S44-S47.	4.3	67
228	RISK OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES WITH AND WITHOUT PRIOR CARDIOVASCULAR EVENTS: RESULTS FROM THE LEADER TRIAL. <i>Canadian Journal of Cardiology</i> , 2017, 33, S126-S127.	0.8	1
229	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. <i>Diabetes Care</i> , 2017, 40, 1763-1770.	4.3	60
230	Metformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular Outcomes. <i>Diabetes Care</i> , 2017, 40, 1787-1789.	4.3	44
231	Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial. <i>Canadian Journal of Diabetes</i> , 2017, 41, S5.	0.4	1
232	The War Is Not Yet Won. <i>Diabetes Care</i> , 2017, 40, 1152-1153.	4.3	1
233	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events. <i>Hypertension</i> , 2017, 70, 907-914.	1.3	12
234	Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 839-848.	13.9	903

#	ARTICLE	IF	CITATIONS
235	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 1228-1239.	13.9	1,455
236	Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 2337-2348.	13.9	322
237	Late-Breaking Science Abstracts From the American Heart Association's Scientific Sessions 2017 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2017. <i>Circulation</i> , 2017, 136, e448-e467.	1.6	13
238	Concerns About Conclusions of Self-monitoring of Blood Glucose—Reply. <i>JAMA Internal Medicine</i> , 2017, 177, 1874.	2.6	0
239	Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 2195-2198.	13.9	31
240	Safety of Degludec versus Glargine in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 1994-1996.	13.9	5
241	Three approaches to glucose monitoring in non-insulin treated diabetes: a pragmatic randomized clinical trial protocol. <i>BMC Health Services Research</i> , 2017, 17, 369.	0.9	3
242	Sitagliptin and risk of fractures in type 2 diabetes: results from the TECOS trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 78-86.	2.2	52
243	Pancreatic Safety of Sitagliptin in the TECOS Study. <i>Diabetes Care</i> , 2017, 40, 164-170.	4.3	49
244	A survey of practices for the use of electronic health records to support research recruitment. <i>Journal of Clinical and Translational Science</i> , 2017, 1, 246-252.	0.3	51
245	Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial. <i>PeerJ</i> , 2017, 5, e3187.	0.9	11
246	The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. <i>Diabetes Care</i> , 2016, 39, 198-205.	4.3	240
247	Chronic Exposure to Arsenic and Markers of Cardiometabolic Risk: A Cross-Sectional Study in Chihuahua, Mexico. <i>Environmental Health Perspectives</i> , 2016, 124, 104-111.	2.8	96
248	Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response. <i>Frontiers in Genetics</i> , 2016, 7, 138.	1.1	2
249	A genome-wide study of lipid response to fenofibrate in Caucasians. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 324-333.	0.7	12
250	Drug Delivery: Microneedles Integrated with Pancreatic Cells and Synthetic Glucose Signal Amplifiers for Smart Insulin Delivery (<i>Adv. Mater.</i> 16/2016). <i>Advanced Materials</i> , 2016, 28, 3223-3223.	11.1	5
251	Microneedles Integrated with Pancreatic Cells and Synthetic Glucose Signal Amplifiers for Smart Insulin Delivery. <i>Advanced Materials</i> , 2016, 28, 3115-3121.	11.1	193
252	More realistic power estimation for new user, active comparator studies: an empirical example. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 462-466.	0.9	2

#	ARTICLE	IF	CITATIONS
253	LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ. <i>Diabetology and Metabolic Syndrome</i> , 2016, 8, 37.	1.2	9
254	Novel measures of inflammation and insulin resistance are related to obesity and fitness in a diverse sample of 11-14 year olds: The HEALTHY Study. <i>International Journal of Obesity</i> , 2016, 40, 1157-1163.	1.6	13
255	Maria Gordon Buse, MD: A Family Affair Through Six Decades of Diabetes Discovery. <i>Diabetes Care</i> , 2016, 39, 852-856.	4.3	1
256	Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1013-1023.	0.8	13
257	Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. <i>Diabetologia</i> , 2016, 59, 1645-1654.	2.9	95
258	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. <i>JAMA Cardiology</i> , 2016, 1, 126.	3.0	196
259	IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 389-397.	1.3	21
260	Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in) <i>TJ ETQq0 0 0 rgBT /Overlock 10 Tf 5 Journal</i> , 2016, 179, 175-183.	1.2	58
261	Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. <i>Diabetes Care</i> , 2016, 39, 1693-1701.	4.3	159
262	Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 40-48.	2.2	33
263	Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 82-91.	2.2	74
264	Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2016, 39, 1186-1201.	4.3	113
265	Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. <i>Diabetes Care</i> , 2016, 39, 1915-1924.	4.3	47
266	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 1834-1844.	13.9	3,898
267	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 1797-1799.	13.9	65
268	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 311-322.	13.9	5,070
269	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. <i>American Heart Journal</i> , 2016, 174, 103-110.	1.2	82
270	Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. <i>New England Journal of Medicine</i> , 2016, 374, 1321-1331.	13.9	877

#	ARTICLE	IF	CITATIONS
271	New Insulins, Biosimilars, and Insulin Therapy. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, S-43-S-55.	2.4	4
272	Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. <i>Diabetes Care</i> , 2016, 39, 701-708.	4.3	150
273	Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 898.	3.8	181
274	Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 990.	3.8	182
275	Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 603-610.	4.3	126
276	Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5. <i>Diabetes Care</i> , 2016, 39, 92-100.	4.3	74
277	Response to Comment on Hempe et al. The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. <i>Diabetes Care</i> 2015;38:1067-1074. <i>Diabetes Care</i> , 2015, 38, e172-e173.	4.3	5
278	Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 560-565.	2.2	11
279	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 232-242.	13.9	2,188
280	CTSA Consortium Consensus Scientific Review Committee (SRC) Working Group Report on the SRC Processes. <i>Clinical and Translational Science</i> , 2015, 8, 623-631.	1.5	7
281	One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 965-973.	2.2	115
282	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , 2015, 58, 429-442.	2.9	598
283	Metabolomic Characteristics of Arsenic-Associated Diabetes in a Prospective Cohort in Chihuahua, Mexico. <i>Toxicological Sciences</i> , 2015, 144, 338-346.	1.4	44
284	LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial: preliminary observations. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 477-486.	2.2	18
285	Regional, age and sex differences in baseline characteristics of patients enrolled in the trial evaluating cardiovascular outcomes with sitagliptin (TECOS). <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 395-402.	2.2	37
286	Racial-Ethnic Disparities in Management and Outcomes Among Children With Type 1 Diabetes. <i>Pediatrics</i> , 2015, 135, 424-434.	1.0	282
287	Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. <i>Diabetes Care</i> , 2015, 38, 1687-1693.	4.3	645
288	Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8260-8265.	3.3	655

#	ARTICLE	IF	CITATIONS
289	The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. <i>Diabetes Care</i> , 2015, 38, 1067-1074.	4.3	133
290	Obesity in Youth with Type 1 Diabetes in Germany, Austria, and the United States. <i>Journal of Pediatrics</i> , 2015, 167, 627-632.e4.	0.9	150
291	Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. <i>Diabetes Care</i> , 2015, 38, 1181-1188.	4.3	194
292	Medications for type 2 diabetes: how will we be treating patients in 50 years?. <i>Diabetologia</i> , 2015, 58, 1735-1739.	2.9	12
293	Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 505-510.	2.2	11
294	Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions. <i>American Journal of Hypertension</i> , 2015, 28, 995-1009.	1.0	18
295	New Insulins and Insulin Therapy. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, S-39-S-46.	2.4	2
296	New Medications for the Treatment of Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, S-119-S-133.	2.4	0
297	Insulin Dose and Cardiovascular Mortality in the ACCORD Trial. <i>Diabetes Care</i> , 2015, 38, 2000-2008.	4.3	33
298	Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2015, 38, 140-149.	4.3	2,326
299	Is insulin the most effective injectable antihyperglycaemic therapy?. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 145-151.	2.2	25
300	Glycemic Targets in Diabetes Care: Emerging Clarity after Accord. <i>Transactions of the American Clinical and Climatological Association</i> , 2015, 126, 62-76.	0.9	6
301	Cardiometabolic Risk Assessments by Body Mass Index Score or Waist-to-Height Ratio in a Multiethnic Sample of Sixth-Graders. <i>Journal of Obesity</i> , 2014, 2014, 1-10.	1.1	19
302	Associations between Arsenic Species in Exfoliated Urothelial Cells and Prevalence of Diabetes among Residents of Chihuahua, Mexico. <i>Environmental Health Perspectives</i> , 2014, 122, 1088-1094.	2.8	48
303	Diabetes and periodontal therapy. <i>Journal of the American Dental Association</i> , 2014, 145, 1208-1210.	0.7	8
304	GLP-1 receptor agonists and basal insulin in type 2 diabetes. <i>Lancet</i> , 2014, 384, 2180-2181.	6.3	5
305	Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 206-214.	2.2	8
306	Knowledge, awareness, and behaviors of endocrinologists and dentists for the relationship between diabetes and periodontitis. <i>Diabetes Research and Clinical Practice</i> , 2014, 106, 428-434.	1.1	23

#	ARTICLE	IF	CITATIONS
307	Effect of Alogliptazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus. JAMA - Journal of the American Medical Association, 2014, 311, 1515.	3.8	206
308	Cognitive Function and Brain Structure in Persons With Type 2 Diabetes Mellitus After Intensive Lowering of Blood Pressure and Lipid Levels. JAMA Internal Medicine, 2014, 174, 324.	2.6	142
309	LEADER 3â€™Lipase and Amylase Activity in Subjects With Type 2 Diabetes. Pancreas, 2014, 43, 1223-1231.	0.5	54
310	A contrast between children and adolescents with excellent and poor control: the T1D exchange clinic registry experience. Pediatric Diabetes, 2014, 15, 110-117.	1.2	102
311	Effect of Relative Weight Group Change on Nuclear Magnetic Resonance Spectroscopy Derived Lipoprotein Particle Size and Concentrations among Adolescents. Journal of Pediatrics, 2014, 164, 1091-1098.e3.	0.9	7
312	Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration. Current Medical Research and Opinion, 2014, 30, 1209-1218.	0.9	8
313	Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial. Diabetes Care, 2014, 37, 1721-1728.	4.3	217
314	Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira). Diabetes Care, 2014, 37, 2926-2933.	4.3	222
315	Dipeptidylâ€peptidaseâ€™4 inhibitors and pancreatic cancer: a cohort study. Diabetes, Obesity and Metabolism, 2014, 16, 1247-1256.	2.2	60
316	The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. Journal of Diabetes and Its Complications, 2014, 28, 874-879.	1.2	19
317	Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management. Diabetes Care, 2014, 37, 2647-2659.	4.3	58
318	Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2014, 16, S-100-S-109.	2.4	0
319	Immune Intervention for Type 1 Diabetes, 2012â€™2013. Diabetes Technology and Therapeutics, 2014, 16, S-85-S-91.	2.4	1
320	Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes, Obesity and Metabolism, 2014, 16, 1016-1027.	2.2	220
321	We Can Change the Natural History of Type 2 Diabetes. Diabetes Care, 2014, 37, 2668-2676.	4.3	75
322	Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naïve patients with type 2 diabetes. Lancet Diabetes and Endocrinology, 2014, 2, 885-893.	5.5	295
323	Bio-Inspired Synthetic Nanovesicles for Glucose-Responsive Release of Insulin. Biomacromolecules, 2014, 15, 3495-3502.	2.6	130
324	Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes. Diabetes, Obesity and Metabolism, 2014, 16, 1065-1069.	2.2	13

#	ARTICLE	IF	CITATIONS
325	Myeloid-derived suppressor cells are increased in frequency but not maximally suppressive in peripheral blood of Type 1 Diabetes Mellitus patients. <i>Clinical Immunology</i> , 2014, 153, 156-164.	1.4	41
326	Electronic Medical Record Cancer Incidence over Six Years Comparing New Users of Glargine with New Users of NPH Insulin. <i>PLoS ONE</i> , 2014, 9, e109433.	1.1	6
327	Exposure to arsenic and cardiometabolic risk in Chihuahua, Mexico. <i>Arsenic in the Environment Proceedings</i> , 2014, , 526-530.	0.0	0
328	Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. <i>Lancet, The</i> , 2013, 381, 117-124.	6.3	466
329	Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. <i>American Heart Journal</i> , 2013, 166, 823-830.e5.	1.2	182
330	Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2013, 36, 1779-1788.	4.3	130
331	Evaluation of the dual peroxisome proliferator-activated receptor α/β agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial. <i>American Heart Journal</i> , 2013, 166, 429-434.e1.	1.2	39
332	Rising temperatures explain past immigration of the thermophilic oak-inhabiting beetle <i>Coraebus florentinus</i> (Coleoptera: Buprestidae) in south-west Germany. <i>Biodiversity and Conservation</i> , 2013, 22, 1115-1131.	1.2	27
333	Diabetes Technology and Treatment in the Pediatric Age Group. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, S-107-S-116.	2.4	3
334	Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN) Tj ETQp 0 0 rg 50 /Overlo	4.3	130
335	Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> 2012;35:1364-1379. <i>Diabetes Care</i> , 2013, 36, 490-490.	4.3	130
336	Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 42-54.	2.2	85
337	Low-Density Lipoprotein Cholesterol versus Particle Number in Middle-School Children. <i>Journal of Pediatrics</i> , 2013, 163, 355-362.e2.	0.9	23
338	Severe Hypoglycemia and Diabetic Ketoacidosis in Adults With Type 1 Diabetes: Results From the T1D Exchange Clinic Registry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3411-3419.	1.8	258
339	Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial. <i>Diabetes Care</i> , 2013, 36, 2162-2168.	4.3	46
340	Salivary proteins associated with hyperglycemia in diabetes: a proteomic analysis. <i>Molecular BioSystems</i> , 2013, 9, 2785.	2.9	57
341	Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin. <i>Diabetes Care</i> , 2013, 36, 3517-3525.	4.3	40
342	Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes Care</i> , 2013, 36, 2254-2261.	4.3	217

#	ARTICLE	IF	CITATIONS
343	Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically Reducing Proinsulin-Specific CD8 ⁺ T Cells in Type 1 Diabetes. <i>Science Translational Medicine</i> , 2013, 5, 191ra82.	5.8	149
344	Most Youth With Type 1 Diabetes in the T1D Exchange Clinic Registry Do Not Meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes Clinical Guidelines. <i>Diabetes Care</i> , 2013, 36, 2035-2037.	4.3	360
345	Five linkage regions each harbor multiple type 2 diabetes genes in the African American subset of the GENNID Study. <i>Journal of Human Genetics</i> , 2013, 58, 378-383.	1.1	14
346	Diabetes Screening With Hemoglobin A1c Versus Fasting Plasma Glucose in a Multiethnic Middle-School Cohort. <i>Diabetes Care</i> , 2013, 36, 429-435.	4.3	58
347	Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1154-1162.	1.8	193
348	BMI Change, Fitness Change and Cardiometabolic Risk Factors Among 8th Grade Youth. <i>Pediatric Exercise Science</i> , 2013, 25, 52-68.	0.5	20
349	Salicylate (Salsalate) in Patients With Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2013, 159, 1.	2.0	219
350	B-vitamins influence arsenic metabolism in Mexico. <i>FASEB Journal</i> , 2013, 27, 1077.20.	0.2	1
351	The Role of Obsessive-Compulsive Symptoms. <i>Zeitschrift für Kinder- Und Jugendpsychiatrie Und Psychotherapie</i> , 2013, 41, 163-171.	0.4	2
352	Gender-based divergence of cardiovascular outcomes in asymptomatic patients with type 2 diabetes: Results from the DIAD study. <i>Diabetes and Vascular Disease Research</i> , 2012, 9, 124-130.	0.9	10
353	The T1D Exchange Clinic Registry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 4383-4389.	1.8	392
354	Single nucleotide polymorphisms in JAZF1 and BCL11A gene are nominally associated with type 2 diabetes in African-American families from the GENNID study. <i>Journal of Human Genetics</i> , 2012, 57, 57-61.	1.1	26
355	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Spectrum</i> , 2012, 25, 154-171.	0.4	28
356	Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 955-958.	4.3	62
357	Reversibility of Fenofibrate Therapy-Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants. <i>Diabetes Care</i> , 2012, 35, 1008-1014.	4.3	114
358	Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. <i>Lancet</i> , 2012, 379, 1489-1497.	6.3	324
359	Exploring salivary proteomes in edentulous patients with type 2 diabetes. <i>Molecular BioSystems</i> , 2012, 8, 1304.	2.9	73
360	Health-Related Quality of Life and Treatment Satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) Trial. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 143-151.	2.4	73

#	ARTICLE	IF	CITATIONS
361	Effects of Sensor-Augmented Pump Therapy on Glycemic Variability in Well-Controlled Type 1 Diabetes in the STAR 3 Study. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 644-647.	2.4	34
362	Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs. <i>Diabetes Research and Clinical Practice</i> , 2012, 96, e66-e69.	1.1	3
363	Strategies for Multivessel Revascularization in Patients with Diabetes. <i>New England Journal of Medicine</i> , 2012, 367, 2375-2384.	13.9	1,573
364	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. <i>Diabetes Care</i> , 2012, 35, 1364-1379.	4.3	3,077
365	Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. <i>Diabetologia</i> , 2012, 55, 1641-1650.	2.9	54
366	Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2012, 55, 1577-1596.	2.9	1,718
367	Effect of Nutrition Changes on Foods Selected by Students in a Middle School-Based Diabetes Prevention Intervention Program: The HEALTHY Experience. <i>Journal of School Health</i> , 2012, 82, 82-90.	0.8	32
368	Cardiovascular risk factors in multi-ethnic middle school students: the <sc>HEALTHY</sc> primary prevention trial. <i>Pediatric Obesity</i> , 2012, 7, 230-239.	1.4	37
369	Diabetes educators' knowledge, opinions and behaviors regarding periodontal disease and diabetes. <i>Journal of Dental Hygiene: JDH / American Dental Hygienists' Association</i> , 2012, 86, 82-90.	0.1	3
370	Individualizing treatment targets in diabetes care. <i>Nature Reviews Endocrinology</i> , 2011, 7, 67-68.	4.3	16
371	Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. <i>New England Journal of Medicine</i> , 2011, 364, 818-828.	13.9	901
372	Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study. <i>Diabetic Medicine</i> , 2011, 28, 715-723.	1.2	29
373	Concomitant Oral Antihyperglycemic Agent Use and Associated Treatment Outcomes After Initiation of Insulin Therapy. <i>Endocrine Practice</i> , 2011, 17, 563-567.	1.1	10
374	Effect of Secular Trends on a Primary Prevention Trial: The HEALTHY Study Experience. <i>Childhood Obesity</i> , 2011, 7, 291-297.	0.8	6
375	Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2011, 154, 103.	2.0	460
376	Efficacy of Anti Hyperglycemic Therapies and the Influence of Baseline Hemoglobin A1C: A Meta-Analysis of the Liraglutide Development Program. <i>Endocrine Practice</i> , 2011, 17, 906-913.	1.1	44
377	Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. <i>Lancet Neurology</i> , The, 2011, 10, 969-977.	4.9	455
378	Student public commitment in a school-based diabetes prevention project: impact on physical health and health behavior. <i>BMC Public Health</i> , 2011, 11, 711.	1.2	27

#	ARTICLE	IF	CITATIONS
379	The effects of the HEALTHY study intervention on middle school student dietary intakes. International Journal of Behavioral Nutrition and Physical Activity, 2011, 8, 7.	2.0	56
380	Baseline Predictors of A1C Reduction in Adults Using Sensor-Augmented Pump Therapy or Multiple Daily Injection Therapy: The STAR 3 Experience. Diabetes Technology and Therapeutics, 2011, 13, 601-606.	2.4	13
381	Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1695-1702.	1.8	125
382	The DURABILITY of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) Trial. Diabetes Care, 2011, 34, 249-255.	4.3	40
383	Effects of Rosiglitazone, Glyburide, and Metformin on β -Cell Function and Insulin Sensitivity in ADOPT. Diabetes, 2011, 60, 1552-1560.	0.3	208
384	The Safety of Incretin-Based Therapies—Review of the Scientific Evidence. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2027-2031.	1.8	143
385	Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2–3 liraglutide clinical development studies. Diabetes and Vascular Disease Research, 2011, 8, 237-240.	0.9	101
386	HLA-A2-Matched Peripheral Blood Mononuclear Cells From Type 1 Diabetic Patients, but Not Nondiabetic Donors, Transfer Insulinitis to NOD-scid/Ånull/HLA-A2 Transgenic Mice Concurrent With the Expansion of Islet-Specific CD8+ T cells. Diabetes, 2011, 60, 1726-1733.	0.3	31
387	Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents. JAMA - Journal of the American Medical Association, 2011, 305, 1659.	3.8	926
388	Urinary Catalytic Iron in Patients with Type 2 Diabetes without Microalbuminuria—a Substudy of the ACCORD Trial. Clinical Chemistry, 2011, 57, 341-344.	1.5	5
389	Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study. Diabetes Care, 2011, 34, 2403-2405.	4.3	102
390	DiabÅ“te et prÅ“diabÅ“te. , 2011, , 319-326.		0
391	Ambient PM _{2.5} Exposure Up-regulates the Expression of Costimulatory Receptors on Circulating Monocytes in Diabetic Individuals. Environmental Health Perspectives, 2011, 119, 778-783.	2.8	22
392	Type 2 Diabetes Mellitus. , 2011, , 1371-1435.		22
393	Type 1 Diabetes Mellitus. , 2011, , 1436-1461.		16
394	North Carolina internists' and endocrinologists' knowledge, opinions, and behaviors regarding periodontal disease and diabetes: need and opportunity for interprofessional education. Journal of Dental Education, 2011, 75, 329-38.	0.7	14
395	Lack of Association Between Thiazolidinediones and Macular Edema in Type 2 Diabetes. JAMA Ophthalmology, 2010, 128, 312.	2.6	50
396	Association of cardiac and vascular changes with ambient PM2.5 in diabetic individuals. Particle and Fibre Toxicology, 2010, 7, 14.	2.8	79

#	ARTICLE	IF	CITATIONS
397	Univariate and Bivariate Linkage Analysis Identifies Pleiotropic Loci Underlying Lipid Levels and Type 2 Diabetes Risk. <i>Annals of Human Genetics</i> , 2010, 74, 308-315.	0.3	9
398	Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial. <i>Diabetes Care</i> , 2010, 33, 983-990.	4.3	389
399	A School-Based Intervention for Diabetes Risk Reduction. <i>New England Journal of Medicine</i> , 2010, 363, 443-453.	13.9	296
400	Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents. <i>Diabetes Care</i> , 2010, 33, 1300-1303.	4.3	163
401	Clinical Care Guidelines: Too Much of a Good Thing?. <i>Diabetes Care</i> , 2010, 33, 2716-2718.	4.3	1
402	DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. <i>Diabetes Care</i> , 2010, 33, 1255-1261.	4.3	308
403	Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2010, 362, 1477-1490.	13.9	588
404	Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2010, 362, 1575-1585.	13.9	3,117
405	Screening for Diabetes and Prediabetes With Proposed A1C-Based Diagnostic Criteria. <i>Diabetes Care</i> , 2010, 33, e174-e174.	4.3	7
406	The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. <i>BMJ: British Medical Journal</i> , 2010, 340, b4909-b4909.	2.4	807
407	Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2010, 362, 1463-1476.	13.9	430
408	Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2010, 363, 233-244.	13.9	1,091
409	Recommendations for Management of Diabetes During Ramadan. <i>Diabetes Care</i> , 2010, 33, 1895-1902.	4.3	318
410	Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2010, 362, 1563-1574.	13.9	2,460
411	Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2010, 363, 311-320.	13.9	792
412	Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. <i>Lancet, The</i> , 2010, 375, 1365-1374.	6.3	228
413	Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. <i>Lancet, The</i> , 2010, 376, 419-430.	6.3	1,182
414	Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. <i>Lancet, The</i> , 2010, 376, 431-439.	6.3	554

#	ARTICLE	IF	CITATIONS
415	Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits. <i>Diabetes Care</i> , 2010, 33, 428-433.	4.3	281
416	Management of Type 2 Diabetes Mellitus. , 2010, , 897-915.		0
417	DURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results. <i>Diabetes Care</i> , 2009, 32, 1007-1013.	4.3	119
418	Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. <i>Diabetes Care</i> , 2009, 32, 187-192.	4.3	624
419	Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. <i>Circulation</i> , 2009, 119, 351-357.	1.6	308
420	Can We Become Victims of Our Own Success?. <i>Diabetes Care</i> , 2009, 32, 2140-2141.	4.3	3
421	Clinical Experience with Continuous Glucose Monitoring in Adults. <i>Diabetes Technology and Therapeutics</i> , 2009, 11, S-93-S-103.	2.4	9
422	Boosting enrollment in neurology trials with Local Identification and Outreach Networks (LIONS). <i>Neurology</i> , 2009, 72, 1345-1351.	1.5	10
423	Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials. <i>Clinical Trials</i> , 2009, 6, 416-429.	0.7	5
424	Racial and Ethnic Differences in Mean Plasma Glucose, Hemoglobin A1c, and 1,5-Anhydroglucitol in Over 2000 Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1689-1694.	1.8	191
425	How Do We Define Cure of Diabetes?. <i>Diabetes Care</i> , 2009, 32, 2133-2135.	4.3	852
426	Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1547.	3.8	718
427	Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP). <i>Diabetes/Metabolism Research and Reviews</i> , 2009, 25, 558-565.	1.7	55
428	Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. <i>Diabetologia</i> , 2009, 52, 17-30.	2.9	635
429	The HEALTHY study: introduction. <i>International Journal of Obesity</i> , 2009, 33, S1-S2.	1.6	9
430	HEALTHY study rationale, design and methods: moderating risk of type 2 diabetes in multi-ethnic middle school students. <i>International Journal of Obesity</i> , 2009, 33, S4-S20.	1.6	63
431	Recruitment and retention strategies and methods in the HEALTHY study. <i>International Journal of Obesity</i> , 2009, 33, S21-S28.	1.6	29
432	Rationale, design and methods of the HEALTHY study nutrition intervention component. <i>International Journal of Obesity</i> , 2009, 33, S29-S36.	1.6	54

#	ARTICLE	IF	CITATIONS
433	Rationale, design and methods of the HEALTHY study physical education intervention component. International Journal of Obesity, 2009, 33, S37-S43.	1.6	35
434	Rationale, design and methods of the HEALTHY study behavior intervention component. International Journal of Obesity, 2009, 33, S44-S51.	1.6	36
435	Social marketing-based communications to integrate and support the HEALTHY study intervention. International Journal of Obesity, 2009, 33, S52-S59.	1.6	48
436	Rationale, design and methods for process evaluation in the HEALTHY study. International Journal of Obesity, 2009, 33, S60-S67.	1.6	57
437	Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. Journal of the American College of Cardiology, 2009, 53, 298-304.	1.2	373
438	Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care, 2009, 32, 193-203.	4.3	2,988
439	Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD). Diabetes Care, 2009, 32, 1224-1230.	4.3	768
440	International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care, 2009, 32, 1327-1334.	4.3	2,651
441	Exenatide for type 2 diabetes – Authors' reply. Lancet, The, 2009, 373, 122-123.	6.3	1
442	Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet, The, 2009, 374, 39-47.	6.3	1,324
443	Adverse events in diabetes drug trial – Authors' reply. Lancet, The, 2009, 374, 1144-1145.	6.3	1
444	A dead heat: target normal glucose levels in the intensive care unit – but with caution. Diabetologia, 2008, 51, 909-910.	2.9	13
445	Development and validation of the Diabetes Numeracy Test (DNT). BMC Health Services Research, 2008, 8, 96.	0.9	141
446	Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine, 2008, 358, 2545-2559.	13.9	7,084
447	Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. American Heart Journal, 2008, 155, 215-223.	1.2	168
448	Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. American Heart Journal, 2008, 156, 623-632.	1.2	84
449	Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet, The, 2008, 372, 1240-1250.	6.3	960
450	Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Current Medical Research and Opinion, 2008, 24, 275-286.	0.9	657

#	ARTICLE	IF	CITATIONS
451	Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. <i>Diabetes Care</i> , 2008, 31, 173-175.	4.3	270
452	Prevalence of the Metabolic Syndrome Among a Racially/Ethnically Diverse Group of U.S. Eighth-Grade Adolescents and Associations With Fasting Insulin and Homeostasis Model Assessment of Insulin Resistance Levels. <i>Diabetes Care</i> , 2008, 31, 2020-2025.	4.3	27
453	FRONTLINE: DIABETES SUPPLEMENTING EDUCATION AND QUALITY IMPROVEMENT IN FAMILY MEDICINE RESIDENCY TRAINING. <i>Annals of Family Medicine</i> , 2008, 6, 88-89.	0.9	4
454	Are prescribing patterns of antidiabetic medications influenced by fears of litigation?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 440-441.	2.9	0
455	Endothelial Dysfunction: Associations with Exposure to Ambient Fine Particles in Diabetic Individuals. <i>Environmental Health Perspectives</i> , 2008, 116, 1666-1674.	2.8	110
456	Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. <i>Current Medical Research and Opinion</i> , 2008, 24, 275-286.	0.9	280
457	Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and Dyslipidemia. <i>Diabetes Care</i> , 2007, 30, 2458-2464.	4.3	172
458	Consensus Statement on the Worldwide Standardization of the Hemoglobin A1C Measurement. <i>Diabetes Care</i> , 2007, 30, 2399-2400.	4.3	268
459	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. <i>Circulation</i> , 2007, 115, 114-126.	1.6	634
460	Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. <i>Clinical Therapeutics</i> , 2007, 29, 139-153.	1.1	272
461	A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2007, 23, 2689-2695.	0.9	12
462	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. <i>Diabetes Care</i> , 2007, 30, 162-172.	4.3	577
463	Glucose Measurement: Confounding Issues in Setting Targets for Inpatient Management. <i>Diabetes Care</i> , 2007, 30, 403-409.	4.3	287
464	Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>American Journal of Cardiology</i> , 2007, 99, S4-S20.	0.7	189
465	Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods. <i>American Journal of Cardiology</i> , 2007, 99, S21-S33.	0.7	491
466	Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. <i>Diabetologia</i> , 2007, 51, 8-11.	2.9	96
467	Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2006, 29, 1963-1972.	4.3	1,089
468	Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. <i>Diabetologia</i> , 2006, 49, 1711-1721.	2.9	373

#	ARTICLE	IF	CITATIONS
469	1,5-Anhydroglucitol and Postprandial Hyperglycemia as Measured by Continuous Glucose Monitoring System in Moderately Controlled Patients With Diabetes. <i>Diabetes Care</i> , 2006, 29, 1214-1219.	4.3	208
470	The Metabolic Syndrome: Time for a Critical Appraisal: Joint Statement From the American Diabetes Association and the European Association for the Study of Diabetes. <i>Yearbook of Endocrinology</i> , 2006, 2006, 40-42.	0.0	0
471	Renewal of FSP1: A marker of fibrogenesis on human renal biopsies. <i>Kidney International</i> , 2005, 68, 1366-1367.	2.6	14
472	The metabolic syndrome: time for a critical appraisal. <i>Diabetologia</i> , 2005, 48, 1684-1699.	2.9	373
473	A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia. <i>Diabetes Care</i> , 2005, 28, 1547-1554.	4.3	777
474	Quality of Diabetes Care in U.S. Academic Medical Centers: Low rates of medical regimen change. <i>Diabetes Care</i> , 2005, 28, 337-442.	4.3	289
475	Recommendations for Management of Diabetes During Ramadan. <i>Diabetes Care</i> , 2005, 28, 2305-2311.	4.3	226
476	The metabolic syndrome. <i>Lancet</i> , The, 2005, 366, 1921-1922.	6.3	26
477	Prevention of Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Trials on the Horizon. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005, 34, 221-235.	1.2	14
478	Muraglitazar, a dual ($\hat{1}\pm/\hat{1}^3$) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. <i>Clinical Therapeutics</i> , 2005, 27, 1181-1195.	1.1	93
479	Prevention of cardiovascular outcomes in type 2 diabetes mellitus: trials on the horizon. <i>Cardiology Clinics</i> , 2005, 23, 211-220.	0.9	1
480	The Metabolic Syndrome: Time for a Critical Appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2005, 28, 2289-2304.	4.3	1,936
481	Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications. <i>British Journal of Psychiatry</i> , 2004, 184, s94-s101.	1.7	18
482	The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2004, 6, 133-156.	2.2	122
483	Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 2628-2635.	4.3	1,196
484	Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2004, 20, 215-223.	0.9	43
485	Prevention or Delay of Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, S47-S47.	4.3	143
486	40th EASD Annual Meeting of the European Association for the Study of Diabetes. <i>Diabetologia</i> , 2004, 47, A1-A464.	2.9	41

#	ARTICLE	IF	CITATIONS
487	Serum 1,5-Anhydroglucitol (GlycoMark [®]): A Short-Term Glycemic Marker. <i>Diabetes Technology and Therapeutics</i> , 2003, 5, 355-363.	2.4	154
488	A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. <i>Journal of Clinical Epidemiology</i> , 2003, 56, 164-170.	2.4	194
489	Follow-up Report on the Diagnosis of Diabetes Mellitus. <i>Diabetes Care</i> , 2003, 26, 3160-3167.	4.3	3,392
490	Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3082-3089.	1.8	528
491	Glitazones and Heart Failure: Critical Appraisal for the Clinician. <i>Circulation</i> , 2003, 108, e57.	1.6	10
492	Should Postprandial Glucose Be Routinely Measured and Treated to a Particular Target? No!. <i>Diabetes Care</i> , 2003, 26, 1615-1618.	4.3	21
493	Should postprandial glucose be routinely measured and treated to a particular target? Connecting the two sides of the debate. <i>Diabetes Care</i> , 2003, 26, 2700-2701.	4.3	1
494	The insulin resistance syndrome and coronary artery disease. <i>Coronary Artery Disease</i> , 2003, 14, 335-348.	0.3	50
495	What We Think and What We Know. <i>Diabetes Care</i> , 2002, 25, 1876-1878.	4.3	5
496	Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 Diabetes<subtitle>Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial</subtitle>. <i>Archives of Internal Medicine</i> , 2002, 162, 1568.	4.3	507
497	The Prevention or Delay of Type 2 Diabetes. <i>Diabetes Care</i> , 2002, 25, 742-749.	4.3	496
498	Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1877-1881.	1.2	74
499	Autoimmune endocrine disease. <i>Current Opinion in Immunology</i> , 2002, 14, 760-764.	2.4	28
500	Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes. <i>Journal of Clinical Psychiatry</i> , 2002, 63 Suppl 4, 37-41.	1.1	6
501	Are α -Hemochromatosis gene mutations a risk factor for type 2 diabetes?. <i>Gastroenterology</i> , 2001, 120, A227.	0.6	0
502	Treatment of postprandial hyperglycemia in type 2 diabetes. <i>Postgraduate Medicine</i> , 2001, 110, 14-9.	0.9	0
503	Panel discussion on achieving glycemic control. <i>Postgraduate Medicine</i> , 2001, 110, 20-5.	0.9	0
504	Combining insulin and oral agents. <i>American Journal of Medicine</i> , 2000, 108, 23-32.	0.6	54

#	ARTICLE	IF	CITATIONS
505	THE USE OF INSULIN ALONE AND IN COMBINATION WITH ORAL AGENTS IN TYPE 2 DIABETES. Primary Care - Clinics in Office Practice, 1999, 26, 931-950.	0.7	8
506	Management of glycemia in type 2 diabetes. Clinical Cornerstone, 1998, 1, 39-57.	1.0	5
507	The PROTECT study: final results of a large multicenter postmarketing study in patients with type 2 diabetes. Clinical Therapeutics, 1998, 20, 257-269.	1.1	26
508	Troglitazone Use in Insulin-Treated Type 2 Diabetic Patients. Diabetes Care, 1998, 21, 1455-1461.	4.3	86
509	The case for a role for postprandial glucose monitoring in diabetes management. Journal of Family Practice, 1998, 47, S29-36.	0.2	6
510	Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus. Cancer Chemotherapy and Pharmacology, 1996, 37, 569-573.	1.1	5
511	The GENNID Study: A resource for mapping the genes that cause NIDDM. Diabetes Care, 1996, 19, 864-872.	4.3	65
512	Small intestine hexose transport in experimental diabetes. Increased transporter mRNA and protein expression in enterocytes.. Journal of Clinical Investigation, 1994, 93, 578-585.	3.9	137
513	The soluble interleukin-6 receptor is generated by shedding. European Journal of Immunology, 1993, 23, 473-480.	1.6	458
514	INHIBITION OF GLUCOSE-STIMULATED INSULIN RELEASE FROM Î²TC3 CELLS AND RODENT ISLETS BY AN ANALOG OF FK506. Transplantation, 1993, 55, 186-191.	0.5	45
515	Human GLUT4/Muscle-Fat Glucose-Transporter Gene: Characterization and Genetic Variation. Diabetes, 1992, 41, 1436-1445.	0.3	55
516	Human intestinal glucose transporter expression and localization of GLUT5. American Journal of Physiology - Cell Physiology, 1992, 262, C795-C800.	2.1	171
517	Human GLUT4/muscle-fat glucose-transporter gene. Characterization and genetic variation. Diabetes, 1992, 41, 1436-1445.	0.3	19
518	Expression and regulation of the human GLUT4/muscle-fat facilitative glucose transporter gene in transgenic mice. Journal of Biological Chemistry, 1992, 267, 11673-6.	1.6	48
519	Polymorphism in exon 4a of the human GLUT4/ muscle-fat facilitative glucose transporter gene detected by SSCP. Nucleic Acids Research, 1991, 19, 4313-4313.	6.5	6
520	Analysis of the gene sequences of the insulin receptor and the insulin-sensitive glucose transporter (GLUT-4) in patients with common-type non-insulin-dependent diabetes mellitus.. Journal of Clinical Investigation, 1991, 88, 1323-1330.	3.9	82
521	Molecular scanning of insulin-responsive glucose transporter (GLUT4) gene in NIDDM subjects. Diabetes, 1991, 40, 1712-1718.	0.3	24
522	Molecular Biology of Mammalian Glucose Transporters. Diabetes Care, 1990, 13, 198-208.	4.3	842

#	ARTICLE	IF	CITATIONS
523	Cloning and characterization of the major insulin-responsive glucose transporter expressed in human skeletal muscle and other insulin-responsive tissues. <i>Journal of Biological Chemistry</i> , 1989, 264, 7776-9.	1.6	326
524	T-cell antigen receptor alpha chain polymorphisms in insulin-dependent diabetes. <i>Journal of Autoimmunity</i> , 1988, 1, 389-397.	3.0	1
525	The NOD mouse: recessive diabetogenic gene in the major histocompatibility complex. <i>Science</i> , 1986, 231, 733-735.	6.0	414
526	Autoimmune Endocrine Disease. <i>Vitamins and Hormones</i> , 1985, 42, 253-314.	0.7	4
527	Major histocompatibility complex restriction fragment length polymorphisms define three diabetogenic haplotypes in BB and BBN rats.. <i>Journal of Experimental Medicine</i> , 1985, 162, 444-458.	4.2	17
528	Two genes required for diabetes in BB rats. Evidence from cyclical intercrosses and backcrosses.. <i>Journal of Experimental Medicine</i> , 1984, 159, 1629-1636.	4.2	93
529	Class I, II and III major histocompatibility complex gene polymorphisms in BB rats. <i>Diabetologia</i> , 1984, 27, 77-79.	2.9	12
530	Specific class II histocompatibility gene polymorphism in BB rats. <i>Diabetes</i> , 1984, 33, 700-703.	0.3	2
531	Lymphocyte abnormalities in the BB rat. <i>Metabolism: Clinical and Experimental</i> , 1983, 32, 83-86.	1.5	28
532	Disordered cellular immunity in type 1 diabetes of man and the BB rat. <i>Survey of Immunologic Research</i> , 1982, 1, 339-51.	0.4	6
533	Kallikrein-induced uterine contraction independent of kinin formation.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1981, 78, 6154-6157.	3.3	35
534	THE ROLE OF THE HUMAN PLACENTA IN THE TRANSFER AND METABOLISM OF INSULIN*. <i>Journal of Clinical Investigation</i> , 1962, 41, 29-41.	3.9	97